Back to Blog

CoQ10, Melatonin and NAC for Oocyte Quality: What the Evidence Actually Says

Dr. Senai Aksoy · · 9 min read
Medically reviewed on 22 July 2026 - Dr. Senai Aksoy
oocyte qualitycoenzyme Q10melatoninN-acetylcysteineIVF supplements
Close editorial still of soft amber capsules and a glass of water on a linen surface, suggesting fertility-supplement discussion before IVF

Key Takeaways

CoQ10, melatonin and N-acetylcysteine are often marketed as "egg quality" supplements before IVF. Trials show small signals on lab markers, such as a few more mature oocytes or better embryo grades, but a live-birth benefit has not been established. ESHRE’s 2023 add-ons document evaluates oral antioxidant therapy as a broad category and does not recommend it routinely in ART. CoQ10 is not a routine recommendation; in diminished ovarian reserve or prior poor response it may be discussed with clear limits on evidence, cost and timing. Foundations such as folic acid, smoking cessation and correcting documented deficiencies support preconception health — they should not be sold as proven ways to raise IVF live-birth rates.

Key evidence: Xu et al. — CoQ10 pretreatment RCT in diminished ovarian reserve (2018) ESHRE — Good practice recommendations on add-ons in reproductive medicine (2023) Showell et al. — Cochrane review: antioxidants for female subfertility (2020)

On this page

The bottom line

CoQ10, melatonin, and N-acetylcysteine are often discussed before IVF because they have plausible antioxidant or mitochondrial effects. Randomized trials show small signals on lab markers, but a clear live-birth benefit has not been established. ESHRE’s 2023 add-ons guidance evaluates oral antioxidant therapy as a broad category rather than endorsing these products one by one, and does not recommend antioxidant therapy routinely in ART. I do not recommend CoQ10 routinely; in diminished ovarian reserve or a previous poor response, a short, evidence-limited discussion may still be reasonable. Foundations such as folic acid, smoking cessation and correction of documented deficiencies support preconception health — they should not be presented as proven ways to raise IVF live-birth rates.

CoQ10, melatonin and NAC before IVF — what the evidence says — Dr Senai Aksoy

What “oocyte quality” actually means

People talk about “oocyte quality” as if it were a score out of ten. In real reproductive biology it is shorthand for three different things, and each one responds to a different lever.

First, meiotic maturity. Only an oocyte that has reached metaphase II can be fertilized. An immature one is set aside in the lab; nothing you swallow the night before will rescue it on the day of the puncture.

Second, chromosomal competence. Chromosomal errors become more common with maternal age, particularly from the late thirties onward. No supplement has been shown to reverse this age-related increase. This is cellular biology, not a failure of self-care or clinic care, and it deserves to be said calmly.

Third, mitochondrial health. Oocytes contain large numbers of mitochondria. Those mitochondria help fuel fertilization and the first divisions of the embryo.

Although some studies report changes in mature-oocyte numbers or embryo morphology, no supplement has been shown reliably to correct age-related chromosomal errors or improve live birth.

Coenzyme Q10

Coenzyme Q10 (ubiquinone) is a cofactor in the mitochondrial respiratory chain. Mitochondrial function may decline with reproductive ageing, so the rationale is intuitive: top up the precursor and an ageing oocyte may have a little more usable energy.

The most-cited trial is Xu et al. (2018), a randomized study in young women with diminished ovarian reserve — not primarily women over 40. CoQ10 (600 mg/day for 60 days before stimulation) was associated with more retrieved oocytes, more high-quality embryos and a lower cancellation rate. So far, encouraging. But in that same study the endpoint that actually matters, live birth, did not reach statistical significance: cumulative live birth was 28.95% versus 15.54% (p = 0.08), and the trial was not powered for that outcome. This trial did not establish a live-birth benefit, and the broader antioxidant literature remains too uncertain to confirm one.

That is the structural problem with the entire “egg quality supplement” literature. Intermediate markers may shift, but the chance of taking a baby home does not clearly improve. More good-looking embryos without more live births is a lab signal, not proof of a better outcome.

So an honest read: CoQ10 is biologically plausible and often discussed as tolerable in the short term, but product quality varies, interactions are possible, and it should be reviewed with the treating clinician. It is not a treatment for age-related aneuploidy, and on current evidence it is not a fertility drug. Any conversation outside the Xu population is an extrapolation from younger DOR cohorts.

Melatonin

A lot was hoped for here, based on melatonin’s antioxidant activity inside the follicle. An early small clinical study by Tamura et al. (2008) reported better fertilization rates in women given 3 mg/day during stimulation. That finding was interesting, but it was not enough to settle the question, and it should not be read as if it were a large randomized trial.

The follow-up has been a lot less tidy. Doses of 3 mg, doses of 6 mg; durations of two weeks, durations of three months; PCOS, poor responders, unselected IVF. Meta-analyses point in different directions depending on which studies they pool. And as with CoQ10, the laboratory signals have not converted into a robust gain in live births. The Cochrane review of antioxidants for female subfertility likewise finds uncertain effects on live birth for antioxidant strategies as a class.

Worth remembering: melatonin is not inert. Daytime drowsiness and a shifted sleep cycle are real side effects. Use in a pregnancy-planning setting, and alongside other medicines, should be reviewed with the treating clinician rather than started casually from a pharmacy shelf.

ESHRE evaluates oral antioxidants collectively and does not recommend antioxidant therapy routinely in ART; this is not a product-specific endorsement or rejection of melatonin.

N-acetylcysteine (NAC)

NAC is a precursor of glutathione, the cell’s main intracellular antioxidant. It also has insulin-sensitising effects, which is why it was first tested in PCOS rather than as a generic “egg” supplement.

In PCOS specifically, it has been compared with metformin in heterogeneous studies. The broader antioxidant and metabolic literature, including the Cochrane review above, does not establish NAC as superior to metformin on ovulation, pregnancy, or live birth.

For “general oocyte quality” outside PCOS? There is no agreed dose, no agreed duration, no convincing positive randomized signal, and no professional society recommendation. The “NAC for eggs” pitch leans on PCOS data extrapolated to a different question, and those are not the same thing.

NAC has been studied in PCOS, but the evidence is too heterogeneous to position it as a standard alternative to metformin or as an egg-quality treatment. It is not included as a recommended fertility therapy in the 2023 international PCOS guideline, which centres metabolic and ovulation-induction decisions on established options such as metformin and, where appropriate, letrozole.

Where ESHRE has stood since 2023

ESHRE’s 2023 add-ons document evaluates oral antioxidant therapy as a broad category rather than endorsing CoQ10, melatonin or NAC individually. Because the evidence for live birth is uncertain, antioxidant therapy is not recommended routinely in ART.

That line — uncertain live-birth benefit, no routine recommendation — is what matters clinically. Individual branded products should not be presented as if ESHRE had graded each one separately and given a product-specific green light.

Who, in practice, might still consider these?

In real consultations, three situations keep coming up.

Diminished ovarian reserve or previous poor response

I do not recommend CoQ10 routinely. In a patient with diminished ovarian reserve or a previous poor response who asks about it, I may discuss the limited evidence, cost, possible adverse effects and the fact that a live-birth benefit has not been established. It should not delay treatment.

Trials have used different formulations and schedules, commonly within a range of 200–600 mg/day for approximately one to three months. These are study regimens, not an established optimal prescription. Supplements should be reviewed with the treating clinician because product quality varies, interactions are possible, and the clinic may advise when to stop them. If the prognosis is poor, the more important conversation is about reconsidering the treatment strategy or discussing legally available alternatives in the appropriate jurisdiction — not about stacking bottles.

The young patient with normal reserve

Here, the biology that CoQ10 is aimed at (mitochondrial decline with reproductive ageing) is usually not the main problem. Spending substantial amounts on premium supplements before a first or second IVF attempt is rarely the highest-value use of that money. Sleep, food and stress management still matter for overall health and treatment experience, but they should not be sold as proven IVF live-birth boosters.

The PCOS patient

NAC has been studied in PCOS, but the evidence is too heterogeneous to present it as a standard metformin alternative or as an egg-quality drug. The 2023 international PCOS guideline does not include NAC among recommended fertility therapies. Metabolic care and ovulation induction remain centred on established options such as metformin and, where appropriate, letrozole.

Foundations that still matter

These measures support general and preconception health, even though most should not be presented as proven ways to increase IVF live-birth rates:

Folic acid is strongly recommended to reduce the risk of neural-tube defects; that is not the same claim as raising IVF live-birth rates. Mediterranean-style diet and sleep data are useful and largely observational. Stress reduction can improve the treatment experience without guaranteeing a better IVF outcome. None of this looks dramatic on a pharmacy shelf, which is exactly why it tends to be undervalued — and why it should not be oversold either.

FAQ

Does CoQ10 actually “rejuvenate” eggs?

No, and this needs to be very clear. It may, modestly, support mitochondrial function. It does not reverse the chromosomal errors that underlie age-related infertility. To date, no supplement has been shown to do that.

Is it safe to combine CoQ10, melatonin and NAC before IVF?

Tolerance is often acceptable in short courses, but that is not a guarantee. Stacking three supplements does not stack three benefits. No good-quality trial has tested the triple combination on live birth, and the chance of side effects (fatigue, gastrointestinal symptoms, disturbed sleep on melatonin) just goes up. Product quality varies, interactions are possible, and any combination should be reviewed with the treating clinician — especially when pregnancy is being planned.

What dose of CoQ10 was used in the trials?

Trials have used different formulations and schedules, commonly within a range of 200–600 mg/day of ubiquinone or ubiquinol for approximately one to three months before stimulation. These are study regimens, not an established optimal prescription.

How long before IVF should you start, if at all?

The biological rationale assumes the supplement is on board during the late stages of follicular development, roughly the two to three months before egg retrieval. Starting a week before stimulation is mostly symbolic. Timing, including when to stop, belongs in a discussion with the treating clinic.

Are these supplements covered by IVF clinics?

In most countries, no. They are usually an out-of-pocket cost. That cost is worth weighing against other uses of the same money — including nutrition support or simply a less stressful preparation period — without assuming any of those choices will raise live-birth rates on their own.

When should you be sceptical of an “egg quality” claim?

When it promises a specific number of “rejuvenated years”. When it cites “a study” without naming it. When it blurs the line between lab markers and live births. And when it is sold to you in the same consultation that describes the treatment plan.

Clinical note

What concerns me is not that a patient asks about CoQ10. It is when several branded supplements are sold as though they can reverse reproductive ageing or compensate for a poor prognosis. I explain that the laboratory signals are preliminary, a live-birth benefit has not been established, and no supplement should delay a treatment decision driven by age, ovarian reserve or previous response.

Dr. Senai Aksoy

Sources

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a founding member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

Instagram YouTube

The content has been created by Dr. Senai Aksoy and medically approved.